Haematology News

Haematology News

Hodgkin lymphoma – The German HD21 trial

hodgkins lymphoma

Hodgkin lymphoma – The German HD21 trial compared BrECADD (brentuximab, etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone) chemotherapy with the current standard BEACOPP for patients with advanced stage Hodgkin lymphoma. The 4-year progression-free survival was significantly better for patients receiving BrECADD, and it also decreased treatment duration to 3-months and had a favourable tolerability. BrECADD sets … Read more

Myeloma – The DREAMM-8 clinical trial

Myeloma – The DREAMM-8 clinical trial that was presented at ASCO and published in the NEJM in June 2024 was a randomised trial comparing belantamab mafodotin, pomalidomide and dexamethasone (BPd) with pomalidomide, bortezomib and dexamethasone (PVd) in lenalidomide-exposed patients who had relapsed/refractory disease after at least one line of treatment. Patients randomised to BPd had … Read more

Updates from American Society of Hematology Meeting 2023

Myeloma_Treatment

Myeloma – the phase 3 PERSEUS trial from the European Myeloma Network randomised approximately 700 newly diagnosed patients with myeloma to treatment with dartumumab, velcade, revlimid and dexamethasone (D-VRD) or VRD followed by an autologous stem cell transplantation, 2 cycles of consolidation with D-VRD or VRD followed by maintenance treatment with dara-revlimid or revlimid alone. … Read more

Exciting new treatment for diffuse-large B-cell lymphoma approved by the European Medicines Agency (EMA).

diffuse-large B-cell lymphoma

In July 2023 the EMA approved Glofitamab, one of the most potent single drugs available for the treatment of relapsed/refractory DLBCL. Glofitamab is a CD20xCD3 bispecific T-cell engager. In a Phase 2 trial of 108 relapsed/refractory DLBCL patients who received glofitamab for a fixed duration an overall response was seen in 50% and a complete … Read more

Update on mantle cell lymphoma 15 October 2023

mantle cell lymphoma

For older non-transplant eligible patients’ initial treatment options are VR-CAP (bortezomib, rituximab, cyclophosphamide, adriamycin and prednisolone based on the LYM 3002 phase 3 trial of VR-CAP vs R-CHOP which showed a longer survival for patients treated with VR-CAP; or bendamustine and rituximab followed by rituximab maintenance. The TRIANGLE study has demonstrated the benefit of adding … Read more

Diffuse-large B-cell lymphoma – Ground breaking new treatment available for relapsed/refractory patients

Diffuse large B-cell lymphoma

For over 30-years autologous stem cell transplantation has been the standard of care for patients with relapsed diffuse-large B-cell lymphoma (DLBCL). The international Zuma-7 trial randomised 359 patients with relapsed/refractory DLBCL or patients with DLBCL who had relapsed within 12-months of their initial therapy to a novel T-cell immunotherapy called CAR-T (chimeric receptor antigen -T-cell … Read more

Hodgkin Lymphoma? A new standard of care for advanced stage patients

hodgkins lymphoma

For decades the standard treatment for patients with advanced Hodgkin lymphoma has been combination chemotherapy with either ABVD or escalated BEACOPP. Approximately 5 years ago a randomised trial showed that brentuximab vedotin (an antibody conjugate) combined with AVD compared with ABVD improved overall survival in adults with Hodgkin lymphoma. The results of the recent SWOG … Read more